Search / 1095 results found

from
to
  • Updated

BRENTWOOD, Tenn., Oct. 21, 2021 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines – both branded and generic – today announced it has a Type C written response meeting with the U.S. Food and Drug Administration ("FDA") regarding a New Drug Application for a Phase 3 program to evaluate the safety and efficacy of CX-101 (naltrexone HCl/bupropion HCl 8 mg/90 mg, extended-release tablets), for the indication of smoking cessation.